Last updated: 2026-09-23 06:55:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SL Science Holding Limited (SLBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.67, with a market capitalization of $964.51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.66 to $14.50. This page covers its latest market performance, valuation, price trends and company information.
$964.51M | |
$1.71 | |
$53.95 | |
$1.66 | |
$1.72 | |
26.04K | |
122.39K | |
-- | |
$14.50 | |
$1.66 | |
-- | |
-- |
SL Science Holding Limited (SLBT) last closed at $1.72 as of 2026-09-22 23:57:00, unchanged from the previous close of $1.72.
During the latest regular trading session, SLBT traded between $1.66 and $53.95, with a volume of 26.04K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, SL Science Holding Limited (SLBT) moved from $2.07 to $1.67, representing a decline of 19.28% ($0.40).
The stock traded between $1.66 and $2.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99.38 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.1%
SLBT is currently trading at $1.67, placing it 0.1% of the way from its 52-week low of $1.66 to its 52-week high of $14.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SL Science Holding Limited (SLBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.